Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche oral Cytovene reduces incidence of CMV in liver transplants by 79%; company plans SNDA filing.

Executive Summary

ROCHE PLANS ORAL CYTOVENE SNDA FOR PROPHYLAXIS OF CMV in liver transplant patients, the company said May 29. Roche made known its plans to file a supplemental NDA for oral ganciclovir when it presented data from a study showing a 79% reduction in the overall incidence of CMV in liver transplant patients at the American Society of Transplant Surgeons meeting in Dallas. Cytovene I.V. is the only product approved for prophylaxis of CMV in solid organ transplants.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel